📰 Immunic News
Page 6 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
April 27, 2023
Issuer: Immunic, Inc. / Key word(s): Personnel Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D. 27.04.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. Strengthens Its Board of Directors with th...
April 26, 2023
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in May 26.04.2023 / 12:30 CET/CEST The issuer is solely responsible
April 24, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has received a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The […]
April 24, 2023
Immunic, Inc. (NASDAQ:IMUX – Get Rating) has been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have issued a buy recommendation on the company. The […]
April 5, 2023
– 50-Week Maintenance Phase Data Shows Dose-Linear Increase in Clinical Remission for Vidofludimus Calcium as Compared to Placebo – – 30 mg Once-Daily Dose of...
April 5, 2023
Issuer: Immunic, Inc. / Key word(s): Study results/Strategic Company Decision Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe
March 30, 2023
Shares of Immunic, Inc. (NASDAQ:IMUX – Get Rating) have been assigned an average rating of “Moderate Buy” from the six research firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on […]
March 2, 2023
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in March 02.03.2023 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences in March NEW YOR...
March 2, 2023
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...
February 23, 2023
/PRNewswire/ -- Immunic, Inc. (NASDAQ: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...